Tamy Kim

477 total citations
13 papers, 307 citations indexed

About

Tamy Kim is a scholar working on Economics and Econometrics, Physiology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Tamy Kim has authored 13 papers receiving a total of 307 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Economics and Econometrics, 9 papers in Physiology and 3 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Tamy Kim's work include Biomedical Ethics and Regulation (9 papers), Health Systems, Economic Evaluations, Quality of Life (9 papers) and Economic and Financial Impacts of Cancer (7 papers). Tamy Kim is often cited by papers focused on Biomedical Ethics and Regulation (9 papers), Health Systems, Economic Evaluations, Quality of Life (9 papers) and Economic and Financial Impacts of Cancer (7 papers). Tamy Kim collaborates with scholars based in United States, Thailand and Canada. Tamy Kim's co-authors include Richard Pazdur, Julia A. Beaver, Paul G. Kluetz, Patricia Keegan, Ann T. Farrell, Rajeshwari Sridhara, Gideon M. Blumenthal, Kirsten B. Goldberg, Lynn Howie and Jinzhong Liu and has published in prestigious journals such as Journal of Clinical Oncology, Nature Reviews Drug Discovery and JNCI Journal of the National Cancer Institute.

In The Last Decade

Tamy Kim

11 papers receiving 300 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tamy Kim United States	4	177	84	80	61	53	13	307
Thomas Gwise United States	10	56 0.3×	96 1.1×	100 1.3×	56 0.9×	15 0.3×	24	316
Shanda Finnigan United States	9	70 0.4×	101 1.2×	38 0.5×	24 0.4×	32 0.6×	18	303
Grace Hsu Canada	7	66 0.4×	78 0.9×	70 0.9×	64 1.0×	11 0.2×	13	277
A.L. Vataire France	13	114 0.6×	157 1.9×	33 0.4×	158 2.6×	17 0.3×	34	478
Gautier Paux France	9	38 0.2×	115 1.4×	64 0.8×	50 0.8×	12 0.2×	26	394
Ronak Saluja Canada	13	121 0.7×	194 2.3×	26 0.3×	65 1.1×	27 0.5×	29	491
Shanthi Sivendran United States	11	41 0.2×	167 2.0×	35 0.4×	30 0.5×	15 0.3×	28	410
Bas Peters Netherlands	15	67 0.4×	167 2.0×	19 0.2×	69 1.1×	16 0.3×	38	464
Jennifer Westrup United States	7	48 0.3×	268 3.2×	34 0.4×	177 2.9×	13 0.2×	12	562
Xiaofei F. Wang United States	14	82 0.5×	283 3.4×	32 0.4×	39 0.6×	51 1.0×	31	638

Countries citing papers authored by Tamy Kim

Since Specialization

Citations

This map shows the geographic impact of Tamy Kim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tamy Kim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tamy Kim more than expected).

Fields of papers citing papers by Tamy Kim

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tamy Kim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tamy Kim. The network helps show where Tamy Kim may publish in the future.

Co-authorship network of co-authors of Tamy Kim

This figure shows the co-authorship network connecting the top 25 collaborators of Tamy Kim. A scholar is included among the top collaborators of Tamy Kim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tamy Kim. Tamy Kim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Srivastava, Geetika, Rupert W. Leong, Abhilasha Nair, et al.. (2024). U.S. FDA analysis of enrollment of Asian patients from India in cancer clinical trials leading to approval from 2010 to 2022.. Journal of Clinical Oncology. 42(16_suppl). e13779–e13779. 1 indexed citations

Agrawal, Sundeep, William F. Pierce, Melanie Royce, et al.. (2024). FDA Approval Summary: Capecitabine Labeling Update under Project Renewal. Clinical Cancer Research. 30(24). 5508–5514.

Leong, Rupert W., Jennifer J. Lee, Geetika Srivastava, et al.. (2024). Underrepresentation of Asian Americans, Native Hawaiians, and other Pacific Islanders (AA & NHPI) in cancer clinical trials that led to FDA approvals in 2010-2022.. Journal of Clinical Oncology. 42(16_suppl). 11026–11026. 1 indexed citations

Agrawal, Sundeep, Shaily Arora, Laleh Amiri‐Kordestani, et al.. (2022). Use of Single-Arm Trials for US Food and Drug Administration Drug Approval in Oncology, 2002-2021. JAMA Oncology. 9(2). 266–266. 43 indexed citations

Kim, Tamy, et al.. (2022). Project facilitate: Innovation and advancement in FDA’s oncology expanded access program.. Journal of Clinical Oncology. 40(16_suppl). e18556–e18556. 1 indexed citations

Scepura, Barbara, et al.. (2021). Oncology Expanded Access and FDA's Project Facilitate. The Oncologist. 26(10). e1880–e1882. 3 indexed citations

Claro, R. Angelo de, Jennifer Gao, Tamy Kim, et al.. (2020). U.S. Food and Drug Administration: Initial Experience with the Real-Time Oncology Review Program. Clinical Cancer Research. 27(1). 11–14. 12 indexed citations

Kim, Tamy, et al.. (2020). Project facilitate: A review of the FDA oncology center of excellence expanded access pilot program.. Journal of Clinical Oncology. 38(15_suppl). 7023–7023. 3 indexed citations

Spillman, Dianne, Shaily Arora, Rajesh Venugopal, et al.. (2020). FDA’s Oncology Center for Excellence Pilots Project Orbis: A framework for concurrent submission and review of oncology products among international partners.. Journal of Clinical Oncology. 38(15_suppl). e14125–e14125.

10.

Vallejo, Jonathon, Paul G. Kluetz, Richard Pazdur, et al.. (2018). Overview of Oncology and Hematology Drug Approvals at US Food and Drug Administration Between 2008 and 2016. JNCI Journal of the National Cancer Institute. 111(5). 449–458. 20 indexed citations

11.

Beaver, Julia A., Lynn Howie, Lorraine Pelosof, et al.. (2018). A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics. JAMA Oncology. 4(6). 849–849. 219 indexed citations

12.

Khozin, Sean, et al.. (2016). Evaluating the potential for digital submission of expedited premarket safety reports to the FDA. Nature Reviews Drug Discovery. 15(10). 670–671. 3 indexed citations

13.

Lemery, Steven J., Sham Mailankody, Dickran Kazandjian, et al.. (2016). Food and Drug Administration analysis of 1332 single patient and emergency use expanded access (compassionate use) requests for patients with cancer over a duration of three years (2012-2014).. Journal of Clinical Oncology. 34(15_suppl). 6523–6523. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact